Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC

(ZFGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/06/2019 | 06:01pm EDT

BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Monday, March 11, 2019 at 5:00 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2018.

Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 2067548. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 8:00 p.m. ET on March 11, 2019 through March 18, 2019 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 2067548.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases. Learn more at www.zafgen.com.

Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Media
Krystle Gibbs
Ten Bridge Communications 
krystle@tenbridgecommunications.com
508-479-6358

Investors
John Woolford
Westwicke
john.woolford@westwicke.com
443-213-0506

zag logo.png


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZAFGEN INC
06/15ZAFGEN : presents Phase II data from Type 2 diabetes drug currently on FDA hold
AQ
06/13ZAFGEN, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/13Zafgen to Present at the JMP Securities Life Sciences Conference
GL
06/11ZAFGEN : Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the Am..
AQ
06/10Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the A..
GL
05/30ZAFGEN, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/30Zafgen Announces Regulatory Update on ZGN-1061
GL
05/09ZAFGEN : 1Q Earnings Snapshot
AQ
05/09ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/09ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -52,7 M
Net income 2019 -54,8 M
Finance 2019 42,5 M
Yield 2019 -
P/E ratio 2019 -0,69x
P/E ratio 2020 -0,71x
EV / Sales2019 infx
EV / Sales2020 -21,6x
Capitalization 38,8 M
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 6,00  $
Last Close Price 1,04  $
Spread / Highest target 669%
Spread / Average Target 477%
Spread / Lowest Target 285%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
John L. LaMattina Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC-78.99%39
GILEAD SCIENCES3.77%82 537
VERTEX PHARMACEUTICALS5.05%44 586
REGENERON PHARMACEUTICALS-20.61%32 370
GENMAB14.24%11 920
SAREPTA THERAPEUTICS INC32.61%10 732